Preliminary Clinical Study of Aclacinomycin A

  • Hisashi Majima
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 70)


Aclacinomycin A (ACM), a new anthracycline antitumor antibiotic, was isolated in 1974 from a culture of Streptomyces galiaeus MA144-MI by Dr. Umezawa et al. in Japan [3]. The structure of ACM is characterized by an ethyl group at position C-13, methyloxy-carbonyl group at C-10, and rhodosamine, 2-deoxyfucose, and cinerulose at position C-7 (Fig. 1).


Cardiac Toxicity Bronchogenic Carcinoma Nitrogen Mustard Bone Marrow Depression Preliminary Clinical Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Furue, H., et al.: Clinical experience with aclacinomycin A. Cancer Chemother. 4, 75 (1977)Google Scholar
  2. 2.
    Oki, T., et al.: Production of nineteen anthracyclic compounds by Streptomyces galilaeus MA 144-M1. J. Antibiot. (Tokyo) 30, 683 (1977)Google Scholar
  3. 3.
    Umezawa, H., et al: New antitumor antibiotics, aclacinomycin A and B. J. Antibiot. (Tokyo). 28, 830 (1975)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • Hisashi Majima
    • 1
  1. 1.Medical Oncology DivisionChiba Cancer Center HospitalChiba 280Japan

Personalised recommendations